Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syntara Limited ( (AU:SNT) ) has shared an update.
Syntara Limited’s Annual General Meeting highlighted the extensive experience of its board members in the pharmaceutical and healthcare industry, emphasizing their roles in global research and development, biotechnology, and life sciences investment. This strategic leadership positions Syntara to leverage their expertise for continued growth and expansion in the international pharmaceutical market.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited operates in the pharmaceutical and healthcare industry, offering products and services across Europe, Asia, and Australia. The company focuses on operational management and has a significant international presence, with leadership experienced in global pharmaceutical markets.
Average Trading Volume: 2,683,659
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
See more insights into SNT stock on TipRanks’ Stock Analysis page.